Series A · Biotech · Paris, France · Founded 2019 · 70–120 employees
Aqemia is pioneering AI-driven drug discovery by combining quantum physics with generative artificial intelligence to design novel therapeutic molecules without relying on experimental data. Founded in 2019 as a spinoff from École Normale Supérieure and CNRS, the company has raised over $100 million in total funding including a recent $38M round led by Cathay Innovation. They have achieved significant pharmaceutical partnerships including a $140M collaboration with Sanofi and have three internal programs currently showing promising results in animal testing. The company is preparing for clinical trials in 2026-2027 and has expanded globally with offices in both Paris and London.
No open roles listed right now.